A Phase 3 Open Label Multicenter Study of the Safety & Efficacy of Brincidofovir CMX001 in the Treatment of Early versus Late Adenovirus Infection. Chimerix Study CMX001-304

Administered By

Awarded By

Contributors

Start/End

  • April 18, 2014 - January 31, 2017